Status:
RECRUITING
Neoadjuvant Immunotherapy of Operable Metastatic Melanoma in Real Life (GCC)
Lead Sponsor:
Centre Hospitalier Universitaire de Besancon
Conditions:
Melanoma Metastatic
Eligibility:
All Genders
18+ years
Brief Summary
This study aims to evaluate efficacy and tolerance of real life neoadjuvant immunotherapy in advanced yet operable melanoma. The complete histological response will be assessed.
Eligibility Criteria
Inclusion
- Patients with operable metastatic melanoma (stage III or IV of American Joint Committee on Cancer \[AJCC\] Stages CLassification) treated with neoadjuvant immunotherapy (anti-PD1 or anti-PD1 + anti-CTLA-4), even if surgery cancelled due to disease progression or complete response or patient\'s refusal to be operated.
- Efficacy of the neoadjuvant immunotherapy histologically of radiologically assessed
Exclusion
- Uveal melanoma
Key Trial Info
Start Date :
March 24 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2025
Estimated Enrollment :
77 Patients enrolled
Trial Details
Trial ID
NCT06586593
Start Date
March 24 2023
End Date
January 1 2025
Last Update
September 19 2024
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Angers
Angers, France
2
CHU de Besançon
Besançon, France
3
Hôpital Avicenne
Bobigny, France
4
CH de Boulogne-sur-Mer
Boulogne-sur-Mer, France